The FDA has approved Hulio (adalimumab-fkjp) subcutaneous injections for the treatment of the following indications:
- Rheumatoid arthritis (RA)
- Juvenile idiopathic arthritis (JIA)
- Psoriatic arthritis (PsA)
- Ankylosing spondylitis (AS)
- Adult Crohn’s Disease (CD)
- Ulcerative colitis
- Plaque psoriasis (Ps)
In various industries, workers may develop certain forms of arthritis due to cumulative or acute trauma, or they may aggravate pre-existing forms of arthritis. This has led to an increase in specialty arthritis drugs making their way into workers’ comp, which makes this a potential drug of interest in workers’ comp.
Hulio is a tumor necrosis factor (TNF) blocker and a biologic. Dosing guidelines vary depending on indication, and the injections are available in three different dosage forms and strengths.
Hulio comes with an increased risk of serious infection, including tuberculosis, which can lead to hospitalization or death. Treatment should not be started in patients during an active infection, and treatment should be discontinued if a patient develops a serious infection or sepsis.
